Endothelium-independent vasodilation effect of hydroxysafflor yellow A in thoracic aorta of Wistar rats

Journal of Medicinal Plants Research

Volumn 5, Issue 11, 2011, Pages 2187-2191

  Zhang, Lin ^a,b   Nie, Peihe ^a   Zhang, Guohua ^a   Rong, Weifang ^a   Zhi, Jianming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Aorta; Ca 2+ channel; Hydroxysafflor yellow a; Vasodilation

Indexed keywords

CALCIUM CHLORIDE; CALCIUM ION; HYDROXYSAFFLOR YELLOW A; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PHENYLEPHRINE; PLANT MEDICINAL PRODUCT; POTASSIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; INCUBATION TIME; ISOLATED ORGAN; MALE; NONHUMAN; RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE; VASODILATATION;

RATTUS; RATTUS NORVEGICUS;

EID: 79959833457     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Dohare P, Varma S, Ray M (2008). Curcuma oil modulates the nitric oxide system response to cerebral ischemia/reperfusion injury. Nitric Oxide, 19: 1-11.
2. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y (2008). Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos., 36: 995-1002.
3. 2+ release by intracellular Mg2+ in cardiac myocytes. J. Gen. Physiol., 132: 721-730.
4. Ji DB, Zhang LY, Li CL, Ye J, Zhu HB (2009). Effect of Hydroxysafflor yellow A on human umbilical vein endothelial cells under hypoxia. Vascul. Pharmacol., 50: 137-145.
5. Jia J, Chai QY, Zhou L, Zhang LW (2009). Antithrombotic Effect of Hydroxysafflor Yellow A. J. Shanxi Uvi., 32: 64-67
6. Jin M, Gao ZC, Wang JF (2004). Research on the Inhibitory effects of Hydroxysafflor Yellow A on the rabbit platelet activation induced by platelet activating factor. J. Beijing Uni. TCM., 27: 32-35.
7. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PKH (2005). Global burden of hypertension: analysis of worldwide. Lancet., 365(9455): 217-223
8. Lawes CMM, Hoorn SV, Rodgers A (2008) (2009). Recommendations for global hypertension monitoring and prevention. Curr. Hypertens Rep., 11: 444-449.
9. 2+ channel. Am. J. Physiol. Cell Physiol., 283: C456-C462.
10. 2+/calmodulin-dependent protein kinase II. Am. J. Physiol. Heart. Circ. Physiol., 295: H1669- H1683.
11. Sun X, Wei XB, Qu SF, Zhao YX, Zhang XM (2010). Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia- reperfusion in rats. Bioorg. Med. Chem. Lett., 20: 4120-4124.
12. Wang L, Kong F, Wu F, Bai Y, Burton R (2005). Preventing chronic diseases in China. Lancet, 366: 1821-1824.
13. Xue JH, Zhang LF, Ma J, Xie MJ (2007). Differential regulation of L-type Ca2+ channels in cerebral and mesenteric arteries after simulated microgravity in rats and its intervention by standing. Am. J. Physiol. Heart. Circ. Physiol., 293: H691-H701.
14. Yang ZF, Yang J, Jia YY, Tian Y, Wen AD (2009). Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers. J Ethnopharmacol., 124: 635-638.
15. Ye SY, Gao WY (2008). Hydroxysafflor yellow A protects neuron against hypoxia injury and suppresses inflammatory responses following focal ischemia reperfusion in rats. Arch. Pharm. Res., 31: 1010-1015.